(S053) Nodal Surveillance With Diffusion-Weighted MRI After Definitive (Chemo) Radiotherapy for HPV-Predominant Squamous Cell Cancers of the Oropharynx and Unknown Primary
Early surveillance imaging with diffusion-weighted MRI at 6–8 weeks following definitive treatment with radiotherapy is feasible and may be predictive of early nodal failure. Further validation in a prospective cohort is warranted.
Yao Yu, MD, Marc Mabray, MD, William Silveira, MD, PhD, Peter Y. Shen, MD, PhD, William Ryan, MD, Alina Uzelac, DO, Sue S. Yom; University of California, San Francisco
BACKGROUND: Diffusion-weighted MRI has been proposed as a method to differentiate treatment effect from persistent or recurrent nodal disease after definitive treatment with radiotherapy.
METHODS: Records and imaging were reviewed for 70 patients treated with definitive radiotherapy with or without chemotherapy for squamous cell carcinomas of the oropharynx or p16-positive unknown primary of the head and neck. A total of 40 patients were available for analysis. Surveillance imaging with magnetic resonance imaging (MRI) was obtained 6–8 weeks after treatment, followed by positron emission tomography/computed tomography (PET/CT) at 12 weeks after treatment. Apparent diffusion coefficient (ADC) values were calculated for each node and for each hemineck. PET/CT results and ADC values were correlated with regional control at 6 months based on histopathology and clinical follow-up.
RESULTS: The mean ADC was significantly lower for lymph nodes corresponding with recurrent disease compared with control at 6 months (1,301 μm2/s vs 2,049 μm2/s; P = .04). Using receiver operating characteristic (ROC) analysis, an optimal threshold of 1,600 μm2/s was identified; lymph nodes with ADC values below this threshold were found to be at higher risk for recurrent disease. Sensitivity and specificity were 100% and 84%, respectively, with positive and negative predictive values of 41% and 100%, respectively. When analyzed by hemineck, the sensitivity and specificity were 100% and 85%, respectively. PET/CT at 12 weeks yielded a sensitivity and specificity of 100% and 85%, respectively. On Kaplan-Meier analysis, ADC was predictive of nodal progression-free survival (P = .00023).
CONCLUSION: Early surveillance imaging with diffusion-weighted MRI at 6–8 weeks following definitive treatment with radiotherapy is feasible and may be predictive of early nodal failure. Further validation in a prospective cohort is warranted.
Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
